Literature DB >> 18698199

American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008.

.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18698199     DOI： 10.1097/DBP.0b013e31318185dc14

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN： 0196-206X            Impact factor:   2.225


× No keyword cloud information.
  20 in total

1.  Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.

Authors:  Craig F Garfield; E Ray Dorsey; Shu Zhu; Haiden A Huskamp; Rena Conti; Stacie B Dusetzina; Ashley Higashi; James M Perrin; Rachel Kornfield; G Caleb Alexander
Journal:  Acad Pediatr       Date:  2012-02-10       Impact factor: 3.107

2.  Cardiac risk assessment before the use of stimulant medications in children and youth.

Authors:  S A Bélanger; A E Warren; R M Hamilton; C Gray; R M Gow; S Sanatani; J M Côté; J Lougheed Frcpc; J Leblanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

Review 3.  Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Authors:  Gary Stiefel; Frank M C Besag
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

4.  Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky Business.

Authors:  Jonathan R Kaltman; Charles I Berul
Journal:  J Cardiovasc Electrophysiol       Date:  2015-08-10

5.  Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents.

Authors:  Laurel K Leslie; Joshua T Cohen; Jane W Newburger; Mark E Alexander; John B Wong; Elizabeth D Sherwin; Angie Mae Rodday; Susan K Parsons; John K Triedman
Journal:  Circulation       Date:  2012-05-03       Impact factor: 29.690

6.  Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry.

Authors:  R Hamilton; C Gray; S A Bélanger; A E Warren; R M Gow; S Sanatani; J-M Côté; J Lougheed; J LeBlanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-11

7.  Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.

Authors:  Rachel Kornfield; Sydeaka Watson; Ashley S Higashi; Rena M Conti; Stacie B Dusetzina; Craig F Garfield; E Ray Dorsey; Haiden A Huskamp; G Caleb Alexander
Journal:  Psychiatr Serv       Date:  2013-04-01       Impact factor: 3.084

Review 8.  Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Authors:  A E Warren; R M Hamilton; S A Bélanger; C Gray; R M Gow; S Sanatani; J-M Côté; J Lougheed; J LeBlanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  Can J Cardiol       Date:  2009-11       Impact factor: 5.223

9.  Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.

Authors:  Paul Hammerness; Katherine McCarthy; Elizabeth Mancuso; Cassandra Gendron; Daniel Geller
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

10.  Adult ADHD and comorbid depression: A consensus-derived diagnostic algorithm for ADHD.

Authors:  Diane McIntosh; Stan Kutcher; Carin Binder; Anthony Levitt; Angelo Fallu; Michael Rosenbluth
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.